HCPCS Level II code J2998 denotes a 1 mg unit of recombinant human plasminogen injection (plasminogen, human-tvmh). As a biologic therapeutic code, it is relevant for clinicians and billing administrators managing care for patients requiring plasminogen replacement. Nationally, accurate use of J2998 affects coverage determinations, claims processing, and aggregate spending on specialty biologics.

Key payers in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of what the code represents, typical sites of service, and the clinical context for use. The publication provides benchmarks for unit-level billing and utilization where available, summaries of payer coverage patterns, and notes on coding considerations specific to a high-cost biologic therapy.

This summary serves clinical, coding, and policy audiences: it clarifies the code’s clinical purpose, lists the primary payers covered in the review, and outlines the types of insights included such as reimbursement benchmarks, policy updates, and operational considerations for billing and documentation. Data not available in the input is noted where applicable.